v3.26.1
INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2025
Disclosure of detailed information about intangible assets [abstract]  
INTANGIBLE ASSETS

8 INTANGIBLE ASSETS

 

   2024   2025 
   S$   S$ 
         
Goodwill   355    355 
Intellectual properties licenses (Note (a))   7,276    1,284 
Computer software licenses (Note (b))   1,980    - 
Acquired customer relationship (Note (c))   51,122    47,855 
Acquired private blood bank license (Note (d))   32,317    11,204 
Acquired technical disclosure (Note (e))   -    64,196 
Total   93,050    124,894 

 

 

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2023, 2024 and 2025

 

  (a) Acquired intellectual properties licenses

 

   2024   2025 
   S$   S$ 
         
Cost:          
At beginning of financial year   62,060    62,060 
Written off   -    (5,350)
At end of financial year   62,060    56,710 
           
Accumulated amortization:          
At beginning of financial year   54,142    54,784 
Amortization charge   642    642 
At end of financial year   54,784    55,426 
           
Carrying value   7,276    1,284 

 

On March 27, 2025, the intellectual properties license is written off due to the termination of the Know-How License agreement.

 

  (b) Computer software licenses

 

   2024   2025 
   S$   S$ 
         
Cost:          
At beginning of financial year   11,737    11,793 
Currency realignment   56    39 
At end of financial year   11,793    11,832 
           
Accumulated amortization:          
At beginning of financial year   7,597    9,813 
Amortization charge   2,160    1,980 
Currency realignment   56    39 
At end of financial year   9,813    11,832 
           
Carrying value   1,980    - 

 

 

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2023, 2024 and 2025

 

  (c) Acquired customer relationship

 

   2024   2025 
   S$   S$ 
         
Cost:          
At beginning of financial year   -    51,122 
Addition   51,122    - 
Currency realignment   -    2,050 
At end of financial year   51,122    53,172 
           
Accumulated amortization:          
At beginning of financial year   -    - 
Amortization charge   -    5,146 
Currency realignment   -    171 
At end of financial year   -    5,317 
           
Carrying value   51,122    47,855 

 

  (d) Acquired private blood bank license

 

   2024   2025 
   S$   S$ 
         
Cost:          
At beginning of financial year   -    43,089 
Addition   43,089    - 
Currency realignment   -    1,727 
At end of financial year   43,089    44,816 
           
Accumulated amortization:          
At beginning of financial year   -    10,772 
Amortization charge   10,397    21,686 
Currency realignment   375    1,154 
At end of financial year   10,772    33,612 
           
Carrying value   32,317    11,204 

 

 

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2023, 2024 and 2025

 

  (e) Acquired technical disclosure

 

   2024   2025 
   S$   S$ 
         
Cost:          
At beginning of financial year   -    - 
Addition   -    65,284 
At end of financial year   -    65,284 
           
Accumulated amortization:          
At beginning of financial year   -    - 
Amortization charge   -    1,088 
At end of financial year   -    1,088 
           
Carrying value   -    64,196 

 

  (f) Amortization expense is analyzed as followed:

 

   2024   2025 
   S$   S$ 
         
Intellectual properties licenses   642    642 
Computer software licenses   2,160    1,980 
Acquired customer relationship   -    5,146 
Acquired private blood bank license   10,397    21,686 
Acquired technical disclosure   -    1,088 
Total   13,199    30,542 
Less: Accounted under          
“Research expenses” (Note 21)   (642)   (642)
 Amortization expense   12,557    29,900 

 

Management has evaluated, assessed and concluded that there is no indication of impairment for the intangible assets as a whole, and accordingly no impairment allowance is necessary.